BC008-1A Injection for Recurrent CNS WHO G4 Glioma

This study is testing a new drug called BC008-1A, which targets a protein called TIGIT on immune cells, in combination with a PD-1 immunotherapy drug for people with grade 4 brain cancer (glioma) that has come back after standard treatment. **You may be eligible if...** - You are 18 or older with confirmed grade 4 brain cancer (glioma) that has returned after standard treatment - Your cancer progression was confirmed by MRI using standard criteria (RANO) - You are not currently a candidate for further surgery - You have a life expectancy of at least 12 weeks - Your general health and organ function are adequate **You may NOT be eligible if...** - You have previously received anti-TIGIT, PD-1, PD-L1, or CTLA-4 drugs (immune checkpoint inhibitors) - You have another active cancer requiring treatment (excluding certain skin and cervical cancers treated previously) - You have an active or historical autoimmune disease - You have active, uncontrolled brain swelling or neurological symptoms requiring high-dose steroids - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.